Efek Samping Penggunaan Hidroksiklorokuin Dalam Terapi Kasus Covid-19
Keywords:
Efek Samping, Hidroksiklorokuin, SARS-CoV-2, Covid-19, CoronavirusAbstract
Hasil studi in vitro menunjukkan bahwa hidroksiklorokuin lebih baik dalam mengobati Covid-19. Pada bebearap artikel menyebutkan efek samping yang berbeda-beda, sehingga akan dilakukan analisis guna mengetahui efek yang paling sering terjadi. Review ini bertujuan untuk menganalisis artikel yang menyatakan adanya efek samping yang sering ditimbulkan akibat penggunaan hidroksiklorokuin dalam tatalaksana Covid-19. Sejumlah 10 artikel didapatkan setelah screening. Terdapat beberapa efek yang sering ditimbulkan akibat penggunaan hidroksiklorokuin pada pasien Covid-19. Hidroksiklorokuin tidak memberikan manfaat terhadap terapi Covid19 dan timbul efek samping selama terapi. Efek samping yang paling sering ditimbulkanya adalah gangguan gastrointestinal (mual, muntah, dan diare) dan jantung (aritmia, perpanjangan gelombang QT).
References
[1] Susilo, A., Rumende, C. M., Ceva, P. W., Widayat Djoko Santoso1, W. D., Yuliant, M., Herikurniawan. 2020. Coronavirus Disease 2019: Review of Current Literatures. Artikel Penyakit Dalam Indonesia, 45-67.
[2] Kemenkes. 2020. Tentang Novel Coronavirus (Ncov). Jakarta: Kemenkes RI.
[3] Picot, S., Marty, A., Anne-LiseBienvenu, A.-L., Blumberg, L., Dupouy-Camet, J., Carnevale, P. 2020. Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19. One Health, 1-5.
[4] Chen, O. J., Danping , L., Li, L. O., Ping, L., Qingnian, X., Lu, X., Ling Yun , Huang Dan, The Song Shuli, Zhang Dandan, Qian Zhiping, Li Tao, Shen Yinzhong, The Lu Of Hongzhou. 2020. A Pilot Study of Hydroxychloroquine in Treatment of Patients with Moderat Covid-19. Journal of Zhejiang University, 215-219.
[5] Skipper, C., Pastick, K., Katelyn A., Bangdiwala, A., Abassi, M., Lofgren, S., DarlishaA.Williams, ElizabethC. Okafor, MatthewF. Pullen, MelanieR. Nicol, PharmD, AlannaA. Nascene, BA; KathyH. Hullsiek, MatthewP. 2020. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19. Annals of Internal Medicine, 1-10.
[6] Abd-Elsalam, S., Esmail, E. S., Khalaf, M., Abdo, E. F., Mohammed , Medhat, Mohamed Samir, Abd El Ghafar, Ossama Ashraf Ahmed, Shaimaa Soliman, Ghada N. Serangawy, dan Mohamed Alboraie. 2020. Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study. The American Society of Tropical Medicine and Hygiene, 1635-1639.
[7] Tang, W., Cao, Z., Wang, Z., Chen, J., Sun, W., Wu, Y., Wei Xiao, Shengyong Liu. 2020. Hydroxychloroquine in Patients Mainly With Mild to Moderate COVID–19: An Open–label. medRxiv.
[8] Chen, O. J., Danping , L., Li, L. O., Ping, L., Qingnian, X., Lu, X., Ling Yun , Huang Dan, The Song Shuli, Zhang Dandan, Qian Zhiping, Li Tao, Shen Yinzhong, The Lu Of Hongzhou. 2020. A Pilot Study of Hydroxychloroquine in Treatment of Patients with Moderat Covid-19. Journal of Zhejiang University, 215-219.
[9] Baulware, Pullen, Bangdiwala, A. S., Pastick, Nicol, Abassi. 2020. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. Hydroxychloroquine as Prophylaxis for Covid-19/ The new england journal of medicine, 1-9.
[10] Horby, P., Mafham, M., Bell, Linsell, L., Phill, L, J. 2020. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. The new england journal of medicin, 1-11.
[11] Saleh, M., Gabriels, J., Chang, D., Kim, B. S., Mansoor, Mahmood. 2020. Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection. Arrhythmia and Electrophysiology.
[12] Mercuro, N. J., PharmD, Christiana, Yen, Davis, Timhoty. 2020. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiology Volume 5, Number 9, 1-6.
[13] Casey, J. D., Jhonson, N., Semler, M., Collins, Aggarwal, Chang. 2020. Rationale and Design of ORCHID: A Randomized Placebo-controlled Clinical Trial of Hydroxychloroquine for Adults Hospitalized with COVID-19. AnnalsATS Volume 17 Number 9, 1-10.
[14] Fitriana, E. I. 2018. Terapi Hidroksiklorokuin pada Anak dengan Nefritis Lupus. Majalah Kedokteran UKI, 51-59.
[15] Pastick, K., Okafor, E., Wang, F., Lofgren, S., Skipper, C., Nico, M. 2020. Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). Open Forum Infectious Diseases, 1-9.
[16] Alberta, V. B. 2020. Retinopati Klorokuin dan Hidroksiklorokuin. CDK, 681-688.
[2] Kemenkes. 2020. Tentang Novel Coronavirus (Ncov). Jakarta: Kemenkes RI.
[3] Picot, S., Marty, A., Anne-LiseBienvenu, A.-L., Blumberg, L., Dupouy-Camet, J., Carnevale, P. 2020. Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19. One Health, 1-5.
[4] Chen, O. J., Danping , L., Li, L. O., Ping, L., Qingnian, X., Lu, X., Ling Yun , Huang Dan, The Song Shuli, Zhang Dandan, Qian Zhiping, Li Tao, Shen Yinzhong, The Lu Of Hongzhou. 2020. A Pilot Study of Hydroxychloroquine in Treatment of Patients with Moderat Covid-19. Journal of Zhejiang University, 215-219.
[5] Skipper, C., Pastick, K., Katelyn A., Bangdiwala, A., Abassi, M., Lofgren, S., DarlishaA.Williams, ElizabethC. Okafor, MatthewF. Pullen, MelanieR. Nicol, PharmD, AlannaA. Nascene, BA; KathyH. Hullsiek, MatthewP. 2020. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19. Annals of Internal Medicine, 1-10.
[6] Abd-Elsalam, S., Esmail, E. S., Khalaf, M., Abdo, E. F., Mohammed , Medhat, Mohamed Samir, Abd El Ghafar, Ossama Ashraf Ahmed, Shaimaa Soliman, Ghada N. Serangawy, dan Mohamed Alboraie. 2020. Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study. The American Society of Tropical Medicine and Hygiene, 1635-1639.
[7] Tang, W., Cao, Z., Wang, Z., Chen, J., Sun, W., Wu, Y., Wei Xiao, Shengyong Liu. 2020. Hydroxychloroquine in Patients Mainly With Mild to Moderate COVID–19: An Open–label. medRxiv.
[8] Chen, O. J., Danping , L., Li, L. O., Ping, L., Qingnian, X., Lu, X., Ling Yun , Huang Dan, The Song Shuli, Zhang Dandan, Qian Zhiping, Li Tao, Shen Yinzhong, The Lu Of Hongzhou. 2020. A Pilot Study of Hydroxychloroquine in Treatment of Patients with Moderat Covid-19. Journal of Zhejiang University, 215-219.
[9] Baulware, Pullen, Bangdiwala, A. S., Pastick, Nicol, Abassi. 2020. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. Hydroxychloroquine as Prophylaxis for Covid-19/ The new england journal of medicine, 1-9.
[10] Horby, P., Mafham, M., Bell, Linsell, L., Phill, L, J. 2020. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. The new england journal of medicin, 1-11.
[11] Saleh, M., Gabriels, J., Chang, D., Kim, B. S., Mansoor, Mahmood. 2020. Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection. Arrhythmia and Electrophysiology.
[12] Mercuro, N. J., PharmD, Christiana, Yen, Davis, Timhoty. 2020. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiology Volume 5, Number 9, 1-6.
[13] Casey, J. D., Jhonson, N., Semler, M., Collins, Aggarwal, Chang. 2020. Rationale and Design of ORCHID: A Randomized Placebo-controlled Clinical Trial of Hydroxychloroquine for Adults Hospitalized with COVID-19. AnnalsATS Volume 17 Number 9, 1-10.
[14] Fitriana, E. I. 2018. Terapi Hidroksiklorokuin pada Anak dengan Nefritis Lupus. Majalah Kedokteran UKI, 51-59.
[15] Pastick, K., Okafor, E., Wang, F., Lofgren, S., Skipper, C., Nico, M. 2020. Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). Open Forum Infectious Diseases, 1-9.
[16] Alberta, V. B. 2020. Retinopati Klorokuin dan Hidroksiklorokuin. CDK, 681-688.
Downloads
Published
2021-05-27
How to Cite
Yulyasti, E., & Dewi, L. M. (2021). Efek Samping Penggunaan Hidroksiklorokuin Dalam Terapi Kasus Covid-19. Prosiding University Research Colloquium, 485–493. Retrieved from https://repository.urecol.org/index.php/proceeding/article/view/1437
Issue
Section
Articles
License
Copyright (c) 2021 Eva Yulyasti, Listiana Masyita Dewi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
